ANTERO-4: VIPUN Gastric Monitoring System in an Erythromycin Model
Status:
Terminated
Trial end date:
2020-03-10
Target enrollment:
Participant gender:
Summary
It has been demonstrated that the VIPUN Gastric Monitoring System (GMS) can discriminate
healthy physiological and pharmacologically-inhibited gastric motility, using a codeine-model
in healthy adults (S60320 / AFMPS80M0687).
Erythromycin is a gastroprokinetic agent, known to stimulate gastric contractility. A single
dose of 200 mg erythromycin has been shown to induce a prolonged period of enhanced phasic
contractile activity.
The primary aim of this investigation is to validate the ability of the VIPUN GMS to
discriminate between normal and pharmacologically-enhanced fasting gastric motility in
healthy adults.
The performance of the VIPUN GMS can be enhanced by data-driven optimization of the VIPUN
Motility Algorithm, used to quantify gastric motility.